Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Wellbutrin Metabolite, Advair Successor In Phase II; NDAs In 2006-2008

Executive Summary

GlaxoSmithKline expects to bring a Wellbutrin (bupropion) metabolite into Phase III studies for major depressive disorder during the second half of 2004

You may also be interested in...



Formularies Should Stress Rx Compliance, Not Co-Pays, Pitney Bowes Says

Covering chronic disease medications as tier one to encourage patient compliance can help manage health care costs, Pitney Bowes Manager-Employee Benefits Design & Development Christine Berman said

GSK Near-Term Pipeline Relies On Line Extensions; “Wall” Of NMEs To Come

GlaxoSmithKline is relying primarily on line extensions and supplemental indications to fill its nearer-term pipeline before the effect of a revamped R&D effort kicks in

GSK Near-Term Pipeline Relies On Line Extensions; “Wall” Of NMEs To Come

GlaxoSmithKline is relying primarily on line extensions and supplemental indications to fill its nearer-term pipeline before the effect of a revamped R&D effort kicks in

Related Content

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel